ライフサイエンスコーパス: reduce the risk of

1 analysis eliminates bias.Although all these approaches can reduce the risk of bias in observational studies, none replac

2 (DHA), an n-3 long-chain polyunsaturated fatty acid, might reduce the risk of bronchopulmonary dysplasia, but appropriat

3 ctive data indicate prophylactic CNS-directed therapies may reduce the risk of CNS involvement; however, no consensus exi

4 Treatment with oral corticosteroids may help to reduce the risk of CNVM development, and anti-VEGF therapy fo

5 ishes CoB-sensitive and CoB-resistant T cell populations to reduce the risk of CoBRR.

6 Strategies aim to reduce the risk of DGF could potentially improve graft surviv

7 cance: Coordinated neoadjuvant and adjuvant immunotherapies reduce the risk of disease relapse after resection of murine

8 ner-, and system-related barriers to diabetes care may help reduce the risk of DR.

9 al inspection can greatly increase the confidence in calls, reduce the risk of false positives, and help characterize com

10 Our results suggest that long-duration breastfeeding may reduce the risk of incident hypertension in middle age.

11 ida species in optisol-GS and should be further explored to reduce the risk of infection.

12 These results suggest that novel oral anticoagulants reduce the risk of intraocular bleeding by approximately one-

13 rt disease and impaired glucose tolerance, acarbose did not reduce the risk of major adverse cardiovascular events, but d

14 mother's milk and avoidance of bovine-origin products might reduce the risk of necrotising enterocolitis, but the absolut

15 mption of dairy products, especially yogurt and cheese, may reduce the risk of overall and CVD mortality.

16 nning of therapeutic and diagnostic radiation treatments to reduce the risk of radiation-related adverse systemic effects

17 olidative autologous stem-cell transplantation (autoSCT) to reduce the risk of relapse, although the benefit of this trea

18 more safe and controlled manner and has to be considered to reduce the risk of retinal break formation and to prevent the

19 ied mRNA vaccine can prevent ZIKV disease and be adapted to reduce the risk of sensitizing individuals to subsequent expo

20 2) systolic BP lowering to a target of <130 mm Hg may reduce the risk of several important outcomes including risk

21 In addition, the elimination of cardiopulmonary bypass may reduce the risk of short-term mortality, renal failure, atria

22 romboprophylaxis with the factor Xa inhibitor betrixaban to reduce the risk of stroke compared with standard-dose enoxapa

23 has occurred and to consider dietary supplements that might reduce the risk of the disease progressing from the intermedi

24 vation of both innate and adaptive immunity can effectively reduce the risk of tumor recurrence after surgery, facilitati

25 ), random assignment to 1 year of trastuzumab significantly reduced the risk of a disease-free survival event (HR 0.76, 9

26 ant characteristics, the use of cytolytic induction therapy reduced the risk of acute rejection by 32% (OR 0.68, 0.62-0.7

27 (all randomized controlled trials) showed that cell therapy reduced the risk of amputation by 37%, improved amputation-fr

28 o a median of 30 mg per deciliter (0.78 mmol per liter) and reduced the risk of cardiovascular events.

29 Among individuals with LDL-C >/=190 mg/dL, pravastatin reduced the risk of coronary heart disease by 27% (P=0.033) a

30 Use of asthma rescue medications at cohort entry reduced the risk of developing obesity (hazard ratio, 0.57; 9

31 Potent P2Y12 inhibitors significantly reduced the risk of MACE by 14% in women (hazard ratio [HR]:

32 Evolocumab reduced the risk of major adverse limb events in all patients

33 systolic blood pressure, compared with standard management, reduced the risk of postoperative organ dysfunction.

34 endent of the IOP, an air tamponade duration beyond 2 hours reduced the risk of rebubbling (HR 0.36 [95% CI 0.18-0.71, P

35 Relative to placebo, evolocumab treatment significantly reduced the risk of the primary end point (1344 patients [9.8

36 mine if dietary supplementation with vitamin D3 and calcium reduces the risk of cancer among older women.

37 ndomized, controlled trial to determine whether minocycline reduces the risk of conversion from a first demyelinating eve

38 ity that hypothermia initiated at 6 to 24 hours after birth reduces the risk of death or disability at 18 months among in

39 r regular consumption of egg protein from age 4 to 6 months reduces the risk of IgE-mediated egg allergy in infants with

40 Our results using Mendelian randomization suggest that ALT reduces the risk of IHD, probably through reducing triglyceri

41 INTERPRETATION: Immediate ART reduces the risk of several severe bacterial infections in HI

42 This variant reduces the risk of severe malaria by 40% and has recently in

43 diet rich in phytochemicals confers benefits for health by reducing the risk of chronic diseases via regulation of oxida

44 Assessing liver health may be important for reducing the risk of future CHF events, particularly among HI

45 The selective delivery spares surrounding normal liver, reducing the risk of liver failure.

46 hypertrophy (LVH) in patients with hypertension and whether reducing the risk of LVH explains the reported cardiovascular

47 ted the clinical benefits of nepafenac 0.3% over vehicle in reducing the risk of postoperative ME, with the integrated an

48 rafts, maintaining or enhancing mechanical properties while reducing the risk of thrombogenesis.

49 Conclusion ZA every 3 months was more CE in reducing the risks of SRE than monthly denosumab.

50 c acid (ZA) every 3 months was noninferior to monthly ZA in reducing the risks of SREs.